KAPA · Kairos Pharma, LTD.
$0.24
0.00 (-1.62%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$5.62M
Shares
23.70M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.24
Open$0.24
Day$0.23–0.25
52W close$0.23–1.97
Avg vol 30d1.7M
Short int364K · 1.5% float · 1.0d
Short vol23%
DataSep 2024–Aug 2026
Filing10-Q · Aug 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−58%
below
Price vs 50-day avg
−29%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
0%
near low
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−62%
trailing
YTD return
−67%
this year
Relative strength
−76%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.54% of float · ▼ -29.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
14 holders — near 2-yr high, broad support
Squeeze score
33
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
13.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−58%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.54% of float · ▼ -29.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
14 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $2
vs 200-day avg -58%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KAPA
this stock
Kairos Pharma, LTD.
|
$5.62M | -66.6% | — | — | 1.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KAPA | -18.2% | -22.5% | -62.4% | -22.5% | -66.6% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -18.7% | -25.5% | -75.9% | -25.5% | -79.4% |
Key facts
CIK
1962011
CUSIP
48301N104
13F (30d)
14 filings
14 filers
Visit website
Investor relations